Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 25 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 11034705

    Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted
  2. US 11026947

    ALK2 inhibitors and methods for inhibiting BMP signaling

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  3. US 11028079

    Small molecule BET bromodomain inhibitors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  4. US 11026905

    STAT3 inhibitors

    Tvardi Therapeutics, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  5. US 11028083

    Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

    The Board of Regents of the University of Texas System · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  6. US 11026931

    Methods for the administration of certain VMAT2 inhibitors

    Neurocrine Biosciences, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  7. US 11028120

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  8. US 2021163596

    IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Jun 3, 2021 · Expires May 29, 2041

    granted
  9. US 11021465

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  10. US 11020391

    CRMP2 sumoylation inhibitors and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  11. US 11021458

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  12. US 11021469

    Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same

    The Board of Regents of the University of Texas System · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  13. US 11021468

    TGF-ß inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  14. US 11013740

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    The Board of Regents of the University of Texas System · Granted May 25, 2021 · Expires May 20, 2041

    granted
  15. US 11013743

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted
  16. US 11013782

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted May 25, 2021 · Expires May 20, 2041

    granted
  17. US 11008304

    Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

    Enanta Pharmaceuticals, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  18. US 11008305

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted May 18, 2021 · Expires May 13, 2041

    granted
  19. US 11007184

    Cancer treatments using combinations of type 2 MEK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  20. US 11008325

    Inhibitors of cancer invasion, attachment, and/or metastasis

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted May 18, 2021 · Expires May 13, 2041

    granted
  21. US 11007183

    Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  22. US 11000513

    Anhydrous compositions of mTOR inhibitors and methods of use

    PALVELLA THERAPEUTICS, INC. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  23. US 11001592

    DNA polymerase IIIC inhibitors and use thereof

    Acurx Pharmaceuticals, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  24. US 11001613

    TFPI inhibitors and methods of use

    Takeda Pharmaceutical Company Limited · Granted May 11, 2021 · Expires May 6, 2041

    granted